This project explores the biology of remission and relapse in patients with antl-neutrophil cytoplasmic autoantibodies (ANCA) glomerulonephritis and small vessel vasculitis (ANCA disease). The genesis of this exploration stems from the clinical observation that some patients with ANCA disease have 30 years of remission while others have repetitive relapses of significant disease. Ideally, patients destined to relapse should have targeted therapy based on the mechanism responsible for their relapse, and those in remission should be spared immunosuppressive therapy. Although clinical predictors of relapse have been Identified, we have only a rudimentary understanding of the mechanistic basis for relapse and remission. This project takes advantage of our longitudinal ANCA disease cohort to examine relapse and remission from several perspectives.
Aim 1 will consider whether relapse is a consequence of aberrant epigenetic regulation of genes encoding the autoantigens myeloperoxidase (MPO) and proteinase 3 (PR3). Building on our basic science findings that epigenetically controlled gene silencing is absent at PR3 and MPO genomic loci In patients with active disease, whether epigenetic silencing of the autoantigen genes is lost during relapse and re-established during remission will be determined.
Aim 2 examines whether relapse stems from aberrant B cell function. Is there clonal expansion of the same autoreactive B cell cloneiIn disease onset and relapse, or is relapse a consequence of a new B cell population reactive to different epitopes of MPO and PR3? Whether relapse is due to dysregulated B cells, in the circulation or tissue, that permit production of autoantibodies will be Investigated.
In Aim 3, T cell regulation is explored with a focus on T regulatory cells that appear functionally "ineffective" in relapsing disease. Is relapse caused by an Imbalance in T regulatory cells and proinflamatory Th17 cells that is restored during remission? These analyses will be performed simultaneously and repetitively over time in ANCA disease patients allowing us to gain a mechanistic understanding of the biology of remission and relapse. These observations have broad implications for the care of patients with ANCA disease and for relapsing and remitting autoimmune disease of all types.
It Is not known why some patients with ANCA disease are treated and stay In long-term remission while others have relapses. This study will help understand the biology of remission and relapse, so treatments can be tailored to the patient. Those who stay in remission could avoid needless toxic immunosuppressive therapy, while those who relapse could be treated with drugs that suppress the cause of disease activity. Insights into the biology of this disease will help in understanding other autoimmune diseases.
|Free, Meghan E; Falk, Ronald J (2016) The Search for a Biomarker of Relapse in ANCA-Associated Vasculitis. J Am Soc Nephrol 27:2551-3|
|Mariani, Laura H; Pendergraft 3rd, William F; Kretzler, Matthias (2016) Defining Glomerular Disease in Mechanistic Terms: Implementing an Integrative Biology Approach in Nephrology. Clin J Am Soc Nephrol 11:2054-2060|
|Yang, Jiajin; Ge, Heng; Poulton, Caroline J et al. (2016) Histone modification signature at myeloperoxidase and proteinase 3 in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Clin Epigenetics 8:85|
|Zhu, Meng-Lei; Bakhru, Pearl; Conley, Bridget et al. (2016) Sex bias in CNS autoimmune disease mediated by androgen control of autoimmune regulator. Nat Commun 7:11350|
|Rhee, Rennie L; Hogan, Susan L; Poulton, Caroline J et al. (2016) Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease. Arthritis Rheumatol 68:1711-20|
|Thrasher, Bradly J; Hong, Lee Kyung; Whitmire, Jason K et al. (2016) Epigenetic Dysfunction in Turner Syndrome Immune Cells. Curr Allergy Asthma Rep 16:36|
|Bakhru, Pearl; Su, Maureen A (2016) Estrogen turns down "the AIRE". J Clin Invest 126:1239-41|
|Jennette, J Charles; Falk, Ronald J (2015) ANCAs are also antimonocyte cytoplasmic autoantibodies. Clin J Am Soc Nephrol 10:4-6|
|Pendergraft 3rd, William F; Badhwar, Anshul K; Preston, Gloria A (2015) Autoantigen complementarity and its contributions to hallmarks of autoimmune disease. J Theor Biol 375:88-94|
|Bunch, Donna O; Mendoza, Carmen E; Aybar, Lydia T et al. (2015) Gleaning relapse risk from B cell phenotype: decreased CD5+ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis. Ann Rheum Dis 74:1784-6|
Showing the most recent 10 out of 75 publications